Calcitonin Gene-Related Peptide Promotes Cellular Changes in Trigeminal Neurons and Glia Implicated in Peripheral and Central Sensitization

Ryan J Cady, Joseph R Glenn, Kael M Smith and Paul L Durham*

Abstract

Background: Calcitonin gene-related peptide (CGRP), a neuropeptide released from trigeminal nerves, is implicated in the underlying pathology of temporomandibular joint disorder (TMD). Elevated levels of CGRP in the joint capsule correlate with inflammation and pain. CGRP mediates neurogenic inflammation in peripheral tissues by increasing blood flow, recruiting immune cells, and activating sensory neurons. The goal of this study was to investigate the capability of CGRP to promote peripheral and central sensitization in a model of TMD.

Results: Temporal changes in protein expression in trigeminal ganglia and spinal trigeminal nucleus were determined by immunohistochemistry following injection of CGRP in the temporomandibular joint (TMJ) capsule of male Sprague-Dawley rats. CGRP stimulated expression of the active forms of the MAP kinases p38 and ERK, and PKA in trigeminal ganglia at 2 and 24 hours. CGRP also caused a sustained increase in the expression of c-Fos neurons in the spinal trigeminal nucleus. In contrast, levels of P2X3 in spinal neurons were only significantly elevated at 2 hours in response to CGRP. In addition, CGRP stimulated expression of GFAP in astrocytes and OX-42 in microglia at 2 and 24 hours post injection.

Conclusions: Our results demonstrate that an elevated level of CGRP in the joint, which is associated with TMD, stimulate neuronal and glial expression of proteins implicated in the development of peripheral and central sensitization. Based on our findings, we propose that inhibition of CGRP-mediated activation of trigeminal neurons and glial cells with selective non-peptide CGRP receptor antagonists would be beneficial in the treatment of TMD.

Background

Peripheral and central sensitization are implicated in the pathology of temporomandibular joint disorder (TMD), which is a musculoskeletal condition characterized by pain and discomfort of the masticatory system including the temporomandibular joint (TMJ) and associated muscles [1,2]. TMD is a prevalent disorder with as much as 70% of the population having at least one TMD symptom and 3-7% of the population seeking treatment for the disorder [3,4]. Activation of trigeminal ganglia neurons, which provide sensory innervation to the joint and muscles of mastication, is implicated in TMD pathology by providing a nociceptive pathway [5]. In response to inflammatory or noxious stimuli, trigeminal ganglia neurons release neuropeptides and other molecules that initiate and maintain neurogenic inflammation in the peripheral tissue that facilitate peripheral sensitization of trigeminal nociceptors [6]. In addition, excitation of trigeminal ganglion neurons leads to activation of second order neurons and glia that promotes central sensitization, hyperalgiesia, and allodynia [7]. Thus, the trigeminal system provides a nociceptive conduit between peripheral inflammation in the joint or muscles and activation of central pain pathways in TMD.

The 37 amino acid neuropeptide calcitonin gene-related peptide (CGRP), which is synthesized and released from trigeminal nerve fibers, is proposed to play a central role in the underlying pathology of TMD [8,9]. CGRP-containing trigeminal nerve fibers are present in the synovial membrane, articular disk, periosseum, and joint capsule of the TMJ [10,11]. Importantly, elevated CGRP levels in TMJ synovial fluid are indicative of mobility impairment and pain associated with...
arthritis [12] and inflammation [13]. CGRP is thought to contribute to TMD pathology by promoting neurogenic inflammation within the capsule via its ability to regulate blood flow, recruit and activate immune cells [14], and sensitize and activate trigeminal nociceptors [15]. In this way, transient increases in CGRP levels would promote inflammation and pain within the joint, while chronically elevated levels would lead to destruction of the TMJ capsule. The pathophysiological effects of CGRP are likely to involve development of peripheral and central sensitization, which are characteristic of TMD pathology.

There is accumulating evidence that supports a central role of CGRP in the initiation and maintenance of peripheral and central sensitization [16-18] via stimulation of neuronal and glial activity within trigeminal ganglia and spinal trigeminal nucleus. The cellular effects of CGRP are mediated via activation of the CGRP receptor, which is expressed by neurons [19] and glia [20] in trigeminal ganglia, and second order neurons and astrocytes in the spinal cord and brainstem nuclei [19,21]. Importantly, the potent peptide CGRP receptor antagonist, CGRP\textsubscript{8-37} has been shown to effectively inhibit vasodilation and neurogenic inflammation in animal models [22,23], and decrease pain thresholds for several days [24]. In addition, the role of CGRP in the development of nociceptive behaviors in response to peripheral inflammatory events has been confirmed in studies of CGRP knockout mice [25]. However, the cellular mechanisms by which CGRP promotes peripheral inflammation and nociception are not well understood. Thus, the goal of our study was to investigate changes in trigeminal ganglia and spinal trigeminal nucleus neurons and glia implicated in the development of peripheral and central sensitization in response to elevated levels of CGRP, as reported during TMJ pathology. Specifically, changes in the expression of the signaling molecules PKA, active ERK and p-38, and the purinergic ion channel P2X\textsubscript{3} have all been reported to play important roles in joint inflammation and pain [26-29].

Results
CGRP increases neuronal expression of MAP Kinases P-p38 and P-ERK in Trigeminal Ganglia
Elevated levels of the phosphorylated active forms of the MAP kinases p38 and ERK are associated with development of peripheral sensitization [30]. To determine whether the expression of P-p38 and P-ERK in the trigeminal ganglia would be increased in response to bilateral TMJ injections of 1 \( \mu \)M CGRP, ganglia were isolated 2 hours and 24 hours post injection and P-p38 and P-ERK staining levels were compared to untreated animals. Changes in P-p38 expression were determined by performing cells counts of positively expressing neurons in the V3 region of the ganglia, which contains cell bodies of neurons that innervate the TMJ capsule. Data are expressed as a percentage of the total number of neurons as identified by the fluorescent nuclear dye DAPI. As seen in Figure 1, 24.30% \pm 0.06 of neurons expressed P-p38 under basal unstimulated conditions. However, at the 2 hour time point, the number of neurons with positive P-p38 staining was significantly increased (57.69% \pm 0.06, \( P < 0.01 \)). Similarly the number of neurons staining positive for P-p38 at 24 hours was significantly increased (81.94% \pm 0.04, \( P < 0.01 \)) compared to both the control and 2 hour CGRP stimulation. These data provide evidence that CGRP activation of trigeminal neurons leads to a prolonged stimulatory effect on neuronal levels of P-p38.

Similar to the P-p38 results, CGRP injection into the TMJ capsule increased expression of P-ERK in neurons. While staining was barely detectable in control ganglia, the expression of the P-ERK, as measured as a change in relative staining intensity, was increased primarily in neurons 2 hours after CGRP injection (Figure 2). However, CGRP was found to greatly stimulate P-ERK expression in both neurons and satellite glial cells within the V3 region of the ganglion at 24 hours. The increase in staining intensity (1.55 \pm 0.11, \( P < 0.01 \)) observed at the 2 hour time point post CGRP injection was significantly greater than control levels (1.00 \pm 0.10), while CGRP levels at 24 hours were significantly higher (3.04 \pm 0.11, \( P < 0.01 \)) than the control and 2 hour values. Thus, elevated levels of CGRP in the joint capsule stimulate a small increase in the neuronal expression P-ERK at 2 hours but induce a much greater response in neurons and glia after 24 hours.

CGRP increases neuronal expression of c-Fos in the spinal trigeminal nucleus
Expression of c-Fos, a member of the early immediate family of transcription factors, was used to study the activation level of second order sensory neurons within the spinal medullary horn. Initially, tissues from the upper spinal cord containing the trigeminal nucleus caudalis (Vc/C1-2 region of the spinal cord 4-5 mm posterior to the obex) in unstimulated animals were stained with DAPI to identify the nuclei of neurons and glia (Figure 3A). Tissues containing the trigeminal nucleus caudalis were then stained with antibodies directed against c-Fos and costained with DAPI. As seen in Figure 3B-C, the number and relative intensity of neuronal c-Fos immunoreactive cells was significantly greater at 2 hours (1.69 \pm 0.07, \( P < 0.05 \)) and 24 hours (1.48 \pm 0.08, \( P < 0.05 \)) post CGRP injection when compared to levels in untreated control animals (1.00 \pm 0.05). Thus, elevated levels of CGRP in the TMJ capsule lead to
activation of second order neurons within the spinal trigeminal nucleus.

**PKA and P2X₃ expression in spinal trigeminal nucleus are elevated in response to CGRP**

The effect of peripheral CGRP on expression of the pro-inflammatory signaling protein PKA and purinergic receptor P2X₃, whose expression correlates with nociceptive transmission, was investigated. As seen in Figure 4, low level expression of PKA (1.00 ± 0.10) was detected in tissues sections from the upper spinal cord containing the trigeminal nucleus caudalis. In contrast, the relative staining intensity for PKA was significantly increased in neurons and glia over control levels in tissues 2 hours (2.01 ± 0.05, *P* < 0.05) and 24 hours (1.85 ± 0.08, *P* < 0.05) post CGRP injection.

Similar to the findings with PKA, CGRP significantly stimulated neuronal P2X₃ expression in the spinal trigeminal nucleus. While minimal P2X₃ immunostaining was observed in control tissues (1.00 ± 0.12), the relative level of staining was greatly increased at 2 hours (2.53 ± 0.11, *P* < 0.05). However at 24 hours, P2X₃ expression had returned to control levels (1.15 ± 0.08) (Figure 5). To confirm expression of P2X₃ in neurons, some tissues were costained with antibodies directed against NeuN, which is a protein expressed in the nucleus of spinal cord neurons. Most of the NeuN positive neuronal cells in the outer lamina also expressed P2X₃ (data not shown). Based on our findings, CGRP injection in the TMJ capsule leads to sustained increases in the levels of PKA in spinal trigeminal nucleus neurons and glia, and a transient elevation in P2X₃.

**CGRP stimulates expression of OX-42 in microglia and GFAP in astrocytes**

The effect of CGRP on microglial activation was investigated using OX-42 antibodies. As seen in Figure 6, low level expression of OX-42 (1.00 ± 0.10) was detected in
tissue sections from the upper spinal cord containing the trigeminal nucleus caudalis. In contrast, the relative staining intensity for OX-42 was significantly increased in tissues 2 hours (2.02 ± 0.04, \(P < 0.05\)) and 24 hours (1.54 ± 0.06, \(P < 0.05\)) post CGRP injection.

Changes in expression of the cytoskeletal protein GFAP were used to determine the activity level of astrocytes in the medullary horn. As shown in Figure 7, control animals express a relatively low level of GFAP immunostaining (1.00 ± 0.13), while animals injected with CGRP exhibited a marked increase in GFAP immunoreactivity after 2 hours (3.90 ± 0.07, \(P < 0.001\)) that was maintained at 24 hours (3.51 ± 0.11, \(P < 0.001\)). Taken together, CGRP causes prolonged spinal trigeminal microglia and astrocyte activation.

**Discussion**

In our study, we found that injection of CGRP into the TMJ capsule resulted in increased expression of proteins implicated in the development and maintenance of peripheral and central sensitization and nociception. The rationale for this study was based on reports that CGRP-containing trigeminal nerve fibers are present in the synovial membrane, articular disk, periosteum, and joint capsule of the TMJ [10,11] and high concentrations of CGRP in TMJ synovial fluid are indicative of mobility impairment and pain associated with arthritis [12] and inflammation [13]. The concentration of CGRP (1 µM) used in our study is similar to levels reported in TMJ exudates collected during inflammatory conditions [31,32]. Our finding that elevated levels of CGRP in the TMJ capsule can stimulate trigeminal neurons is in agreement with the proposed role of CGRP in TMD by promoting local inflammation as well as pain transmission from peripheral tissues to the CNS [33]. Towards this end, we found that CGRP stimulation of trigeminal neurons increased neuronal expression of P-p38 and P-ERK at 2 and 24 hours and increased P-ERK staining.

---

**Figure 2** CGRP stimulates increased P-ERK expression in trigeminal ganglia neurons and satellite glia. Sections of the postrolateral portion of the ganglion (V3) were obtained from untreated animals (CON), or animals injected with CGRP in each TMJ capsule. (A) Images of neuron-satellite glial regions stained for P-ERK are shown in the top panels. Magnification bar = 50 µm. The bottom panels are the same sections co-stained for P-ERK and DAPI. (B) The average fold change ± SEM of P-ERK staining intensity from control values, whose mean was made equal to one, is reported (n = 3 independent experiments) \(^*\) \(P < 0.01\) when compared to control levels, while \(^†\) \(P < 0.01\) when compared to CGRP stimulated levels at 2 hours.
intensity in satellite glial cells in trigeminal ganglia at 24 hours. Both p-38 and ERK are members of the MAP kinase family of signal transduction enzymes activated in response to inflammatory stimuli, and are known to play an important role in the development of peripheral sensitization [28,34,35]. The MAP kinases are reported to mediate sensitization of primary and second order nociceptive neurons by increasing neuronal ion channel
expression and activity, and expression of membrane receptors associated with nociception [28,36]. In addition, p38 and ERK are known to stimulate synthesis and secretion of cytokines from glial cells that promote and maintain a hyperexcitable state of neurons [6,28,37]. Further evidence of the importance of MAP kinases in the induction of peripheral sensitization and persistent pain was provided by results from studies in which blocking MAP kinase activity with specific inhibitors suppressed nociceptive responses and sensitization [28,38,39].

Results from our study provide evidence that elevated TMJ levels of CGRP can promote cellular events associated with the development of central sensitization. For example, we found that c-Fos expression in second order neurons within the spinal trigeminal nucleus was increased at 2 hours, and remained significantly elevated at 24 hours in response to bilateral injections of CGRP. In addition, upregulation of OX-42, a biomarker indicative of microglial activation [40], was observed at 2 and 24 hours after CGRP injection. CGRP also induced a large increase in expression of GFAP at 2 hours that remained at a similar elevated level at 24 hours. GFAP is an intermediate cytoskeleton filament protein selectively localized to mature astrocytes and, thus, serves as a biomarker of astrocyte activation [41]. Based on our findings, we propose that CGRP facilitates development of TMD by promoting an enhanced state of astrocyte and microglia activity, which is characteristic of central sensitization, persistent pain states, and nociceptive behaviors [6,42].

We also found that levels of PKA and P2X3 were elevated in response to CGRP injection into the TMJ capsule. However, while CGRP caused a more sustained increase in PKA expression in spinal neurons and glia, elevated levels of CGRP in the capsule resulted in a transient increase in neuronal expression of P2X3. Activation of intracellular signaling pathways involving PKA are known to play a key role in the induction and maintenance of central sensitization and persistent pain by

---

Figure 4 PKA levels are elevated in the spinal trigeminal nucleus in response to CGRP. Spinal cord sections were obtained from control animals (CON), animals 2 hours post CGRP injections, or animals 24 hours post CGRP injection. (A) Images of spinal cord tissues stained for PKA are shown in the top panels. Magnification bar = 50 μm. The same sections costained for PKA and DAPI are displayed in the bottom panels. (B) The average fold change ± SEM of PKA staining intensity from control values is reported (n = 3). * P < 0.05 when compared to control values.
phosphorylation of glutamate receptors and ion channels [43-45], and increasing expression of pro-inflammatory and pro-nociceptive genes. Furthermore, blocking PKA signaling results in reduction of inflammation-induced hyperalgesic behaviors [46,47]. Findings from our study provide evidence that neuronal levels of the purinergic receptor P2X3 were also significantly elevated at 2 hours after a single CGRP injection. Notably, the inflammatory and nociceptive effects of ATP are known to involve activation of P2X receptors, which are upregulated in sensitized nociceptive neurons [48-50]. In particular, activation of heteromeric P2X2/3 or homomeric P2X3 receptors, which are abundantly expressed by trigeminal ganglion neurons [51] is reported to mediate acute and chronic pain in response to inflammation or nerve injury [49,52-55]. Based on data from prior studies, we propose that elevated peripheral levels of CGRP increase membrane expression and sensitization of P2X3 receptors on second order neurons. Taken together, our findings demonstrate that elevated levels of CGRP, as reported in TMD, promote cellular changes in spinal trigeminal neurons and glia that temporally correlate with initiating and promoting central sensitization.

**Conclusions**

In this study, we provide evidence that elevated levels of CGRP leads to cellular changes in proteins implicated in the development and maintenance of peripheral and central sensitization. Although not directly demonstrated in our study, we speculate that CGRP stimulation of MAP kinases, PKA, and P2X3 would also lead to increased nociceptive responses to thermal, mechanical, and chemical stimuli. Interestingly, data from recent phase II clinical studies provide evidence that a non-peptide CGRP receptor antagonist was effective as an abortive therapy for migraine [56], a disease that involves activation of trigeminal neurons, elevated levels of CGRP, and peripheral and central sensitization. Thus,

---

**Figure 5** CGRP causes a transient increase in P2X3 expression in the spinal trigeminal nucleus at 2 and 24 hours. Sections of spinal cord were obtained from control animals (CON), animals 2 hours post CGRP injections or animals 24 hours post CGRP injection. (A) Images of spinal cord tissues stained for P2X3 are shown in the top panels. Magnification bar = 50 μm. The same sections costained for P2X3 and DAPI are displayed in the bottom panels. (B) The average fold change ± SEM of P2X3 staining intensity from control values is reported (n = 3). * P < 0.05 when compared to control values.
based on our findings as well as others, we postulate that blocking the cellular effects of CGRP with the use of non-peptide antagonists would be beneficial in the treatment of TMD.

Methods

Animals

All animal studies were approved by the Institutional Animal Care and Use Committee at Missouri State University and were conducted in compliance with all established guidelines in the Animal Welfare Act and National Institutes of Health. Adult male Sprague-Dawley rats (200-250 grams; Charles River Laboratories, Wilmington, MA) were housed in structurally sound, clean plastic cages on a 12 hour light/dark cycle with unrestricted access to food and water. A concerted effort was made to reduce the suffering and number of animals used in this study. In addition, food and water consumption, weight, and grooming behaviors were recorded daily to monitor the overall health of the animals.

CGRP injection as a model of TMJ inflammation

Rats were anesthetized by inhalation of 3.0% isoflurane (VetEquip, Pleasanton, CA). For the CGRP studies, rat CGRP (American Peptide, Sunnyvale, CA) was injected into each TMJ capsule (25 μl per injection; 1 μM in sterile water), while some animals were left untreated and served as controls. Rats were sacrificed by CO2 asphyxiation either 2 hours or 24 hours post injection.

Tissue isolation and preparation

Trigeminal ganglia and spinal cord from the spinomedullary junction (Vc/C1-2) transition zone containing the trigeminal nucleus caudalis were removed from all rats following CO2 asphyxiation. Tissues were placed in a solution of 4% paraformaldehyde overnight followed by incubation in 15% sucrose in water at 4°C for 1 hour and then 30% sucrose overnight at 4°C. Trigeminal ganglia and spinal cord tissues were mounted with OCT Compound (Sakura Finetek, Torrance, CA) such that the ventral surface of the tissue was in contact with the

Figure 6 Elevated expression of OX-42 in microglia
Sections of spinal cord were obtained from control animals (CON), animals 2 hours post CGRP injections, or animals 24 hours post CGRP injection. (A) Images of spinal cord tissues stained for OX-42 are shown in the top panels. Magnification bar = 50 μm. The same sections costained for OX-42 and DAPI are shown in the bottom panels. (B) The average fold change ± SEM of OX-42 staining intensity from control values is reported (n = 3). * P < 0.05 when compared to control values.

|                  | CON  | 2 h  | 24 h |
|------------------|------|------|------|
| OX-42 Relative Intensity | 1.00 ± 0.10 | 2.02 ± 0.04* | 1.54 ± 0.06* |

* P < 0.05 when compared to control values.
slide, quickly frozen, and stored at -20°C. Fourteen-micron longitudinal sections of the entire trigeminal ganglion tissue were serially prepared using a cryostat (Microm HM 525, Thermo Scientific, Waltham, MA) set at -20°C. Spinal cord tissue containing spinal trigeminal nucleus was sectioned transversely at a distance of 4-5 mm posterior to the obex in 20 μm tissue sections using a cryostat set at -18°C. All sections were mounted on Superfrost Plus microscope slides (Fischer Scientific, Pittsburg, PA). Each slide used for immunohistochemistry contained at least one section from each experimental condition.

Immunohistochemistry

Slides containing trigeminal ganglia or spinal cord tissue were permeabilized with 0.1% Triton X-100 plus 5% donkey serum in PBS for 20 minutes. Trigeminal ganglia sections were incubated overnight at 4°C with a P-p38 rabbit monoclonal antibody (1:200; Bioworld, St. Louis Park, MN). Spinal cord sections were incubated for 3 hours at room temperature with a mouse GFAP monoclonal antibody (1:500; Dako, Glostrup Denmark), mouse PKA polyclonal antibodies (1:100; BD Biosciences, San Jose, CA), rabbit c-Fos polyclonal antibodies (1:200; Abcam, Inc, Cambridge, MA), rabbit P2X3 polyclonal antibodies (1:1000; ThermoScientific, Rockford, IL), mouse NeuN monoclonal antibody (1:1000; Millipore), or a mouse OX-42 monoclonal antibody (1:200; Abcam). All sections were incubated for 1 hour at room temperature with either Alexa Fluor 594 donkey anti-mouse (PKA, GFAP, OX-42, NeuN) or rabbit (P-p38, P-ERK, c-Fos, P2X3; Invitrogen, Carlsbad, CA) diluted 1:500 in PBS, to detect immunofluorescent proteins by UV-fluorescence microscopy. Sections were costained with the nuclear dye 4’6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA) and mounted in Vectashield (H 1200; Vector Laboratories). Images were collected from both trigeminal ganglia and both sides of

![Image](image_url)
spinal cord tissues at 400 × magnification using an Olympus DP70 camera mounted on an Olympus BX41 fluorescent microscope (Olympus, Center Valley, PA) or a Zeiss Axiocam mRm camera mounted on a Zeiss Imager Z1 fluorescent microscope equipped with an ApoTome.

Measurement of cell counts and staining intensity

Images containing the mandibular branch (V3) of the middle portion of the trigeminal ganglion or regions of spinal cord tissue containing the trigeminal nucleus caudalis were used for analysis. Three images were taken from 3 independent experiments, resulting in 9 images for all cell count or intensity measurements, which were performed by two researchers blinded to the experimental conditions. To determine changes in expression of P-p38 in ganglia, the number of P-p38 positive neurons under each experimental condition were counted and expressed as a ratio of the total number of neurons identified by DAPI staining in each field. To quantify the staining intensity of P-ERK in the trigeminal ganglia, the mean gray intensity of 3 circular regions from areas containing a single neuron and associated surrounding satellite glial cells were measured and the mean gray intensity from an area containing only Schwann cells and fiber tracts was subtracted as background. To evaluate the expression of proteins in the trigeminal nucleus caudalis, images consisting of consecutive non-overlapping regions, containing cells from lamina I-IV were analyzed for each experimental condition. The staining intensity in spinal cord tissue was determined by measuring the mean gray intensity from 3 regions of staining in the trigeminal nucleus caudalis and subtracting the intensity from areas containing only background staining. The relative staining intensity measurements were determined using Image J software (Ver 1.43, Wayne Rasband, National Institutes of Health, Bethesda, MD) and based on our previously published protocols [26,57,58]. The fold change in staining intensity was defined as the mean change in relative intensity in the experimental condition when compared to mean levels of the unstimulated control tissue, which was set equal to one. Statistical analysis was performed using the non-parametric Mann-Whitney U test. Results were considered significant when P < 0.05. All statistical tests were performed using SPSS (Version 16, IBM, Chicago, IL).

Acknowledgements

This study was funded by NIH (DE017805) and a research grant from Merck.

Authors’ contributions

RC contributed to data acquisition and analysis and preparation of the final manuscript, KS contributed to experimental design and acquisition of data, JS contributed to acquisition of data and manuscript preparation, PD contributed to experimental design, analysis and interpretation of data, and drafted as well as critically revised the manuscript. All the authors read and approved the final manuscript.

Competing interests

Paul Durham has served as a consultant and has received grant funding from Merck & Co. The other authors declare that they have no competing interests.

Received: 17 June 2011 Accepted: 6 December 2011
Published: 6 December 2011

References

1. Sessle BJ: Neural mechanisms and pathways in craniofacial pain. Can J Neural Sci 1999, 26(Suppl 3):S7-11.
2. Sessle BJ: Peripheral and central mechanisms of orofacial pain and their clinical correlates. Minerva Anestesiol 2005, 71:117-136.
3. Oksenberg J: Management of Temporomandibular Disorders and Occlusion. 6 edition. St. Louis, MO, 2008.
4. Bonjardim LR, Lopes-Filho RI, Aram Đo G, Albuquerque RL, Goncalves SR: Association between symptoms of temporomandibular disorders and gender, morphological occlusion, and psychological factors in a group of university students. Indian J Dent Res 2009, 20:190-194.
5. Shankland W: The trigeminal nerve. Part IV: the mandibular division. Journal of Craniomandibular Practice 2001, 19:153-161.
6. Ji RR: Peripheral and central mechanisms of inflammatory pain, with emphasis on MAP kinases.Curr Drug Targets Inflamm Allergy 2004, 3:299-303.
7. Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGrage SC, Wei F, Dubner R, Ren K: Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. The Journal of Neuroscience: the official journal of the Society for Neuroscience 2007, 27:6006-6018.
8. Kopp S: Neuroendocrine, immune, and local responses related to temporomandibular disorders. J Orofac Pain 2001, 15:S-9.
9. Sessle B: New insights into peripheral chemical mediators of temporomandibular pain and inflammation. J Orofac Pain 2001, 15:S-5.
10. Kido M, Kiyoshima T, Kondo T, Ayasaka N, Moroi R, Terada Y, Tanaka T: Distribution of substance P and calcitonin gene-related peptide-like immunoreactive nerve fibers in the rat temporomandibular joint. J Dent Res 1993, 72:592-598.
11. Uddman R, Grunditz T, Kato J, Sundler F: Distribution and origin of nerve fibers in the rat temporomandibular joint capsule. Anat Embryol 1998, 197:273-282.
12. Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E: Neuropeptides in the arthritic TMJ and symptoms and signs from the stomatognathic system with special considerations to rheumatoid arthritis. J Orofac Pain 1995, 9:215-225.
13. Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E: Relation between intra-articular temperature of the arthritic temporomandibular joint and presence of calcitonin gene-related peptide in the joint fluid. A clinical study. Acta Odontol Scand 1993, 51:285-291.
14. Ottosson A, Edvinsson L: Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997, 17:166-174.
15. Seybold V: The Role of Peptides in Central Sensitization. Handbook of Exp Pharma 2009, 194:451-491.
16. Seybold V, McCarson K, Mermelstein P, Grath R, Abrahams J: Calcitonin gene-related peptide regulates expression of neurokinin-1 receptors by rat spinal neurons. The Journal of Neuroscience 2003, 23:1816-1824.
17. Hucho T, Levine JD: Signaling pathways in sensitization: toward a nociceptor cell biology. Neurology 2007, 55:365-376.
18. Li D, Ren Y, Xu X, Zou X, Fang L, Lin Q: Sensitization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related Peptide driven by dorsal root reflexes. J Pain 2008, 9:1155-1168.
19. Lennertz JK, Ruhl V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Meszlinger K: Calcitonin receptor-like receptor (CRLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the trigeminal nociceptive system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 2008, 507:1277-1299.
20. Thalakoti S, Patil V, Dandodaram S, Vause CV, Langford LE, Freeman SE, Durham PL: Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 2007; 47:1008-1023.

21. Van Rossum D, Hanisch U, Quinlan R: Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997; 21:649-678.

22. Hughes SR, Brain SD: A calcitonin gene-related peptide (CGRP) antagonist (CGRP8-37) inhibits microvascular responses induced by CGRP and capsaicin in skin. Br J Pharmacol 1991; 104:738-742.

23. Edvinsson L, Nilsson E, Jansen-Olesen I: Inhibitory effect of BIBN4096BS, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 2007; 150:633-640.

24. Jang JH, Nam TS, Paik KS, Leem JW: Involvement of peripherally released substance P and calcitonin gene-related peptide in mediating mechanical hyperalgesia in a traumatic neuropathy model of the rat. Neurosci Lett 2004; 360:129-132.

25. Zhang L, Hoff A, Wimalawansa S, Cote G, Gagel R, Westlund K: Arthritic calcitonin/calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain 2001; 89:265-273.

26. Cady RJ, Hirst JJ, Durham PL: Dietary grape seed polyphenols repress neuron and glia activation in trigeminal ganglion and trigeminal nucleus caudalis. Mol Pain 2010; 6:69.

27. Shinoda M, Ozaki N, Asai H, Nagamine K, Sugura Y: Changes in P2X3 receptor expression in the trigeminal ganglion following monoaethoxylate of the temporomandibular joint in rats. Pain 2005; 116:42-51.

28. Ji RR, Gereau RW IV, Malcangio M, Strichartz GR: MAP kinase and pain. Brain Res Rev 2009; 60:135-148.

29. Sluka KA, Price MP, Beese NM, Stucky CL, Wieemien JA, Welch MJ: Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1. Pain 2003; 106:229-239.

30. Ji R, Gereau RW IV, Malcangio M, Strichartz GR: MAP kinase and pain. Brain Res Rev 2009; 60:135-148.

31. Alerstgren P, Appelgren A, Appelgren B, Kopp S, Lundeborg T, Theodorsson E: Co-variation of neuropeptide Y, calcitonin gene-related peptide, substance P and neurokinin A in joint fluid from patients with temporomandibular joint arthritis. Arch Oral Biol 1995; 40:127-135.

32. Holmlund A, Ekbom A, Hansson P, Lind J, Lundenberg T, Theodorsson E: Concentration of neuropeptide substance P, Neurakin A, calcitonin gene related peptide, neuropeptide Y and vasoactive intestinal polypeptide in the synovial fluid of the human temporomandibular joint. Int J Oral Maxillofac Surg 1991; 20:228-231.

33. Geppetti P, Del Bianco E, Santocchi R, Maggi C, Tramontana M: Low pH-induced release of calcitonin gene-related peptide from capsaicin-sensitive sensory nerves: mechanism of action and biological response. Neurosci 1991; 41:295-301.

34. Cheng J, Ji RR: Intracellular signaling in primary sensory neurons and persistent pain. Neurochem Res 2008; 33:1970-1978.

35. Takeda M, Takahashi M, Matsumoto S: Contribution of the activation of satellite glia in sensory ganglia to pathological pain. Neurosci Biobehav Rev 2009; 33:784-792.

36. Cheng JK, Ji RR: Intracellular signaling in primary sensory neurons and persistent pain. Neurochem Res 2008; 33:1970-1978.

37. Crown ED, Ye Z, Jobanputra KM, Xu GY, Mckeech DJ, Huleabouch CE: Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are correlated with the expression of at-Ievel mechanical alldodynia following spinal cord injury. Exp Neural 2006; 199:397-407.

38. Milligan ED, Twining C, Chaucer M, Biedenkapp J, O'Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. The Journal of neuroscience: the official journal of the Society for Neuroscience 2003; 23:1026-1040.

39. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Kaizumi S, Inoue K: Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004; 45:89-95.

40. Suter MR, Wen YR, Decoster L, Ji RR: Do glial cells control pain? Neurogn Glia Biol 2007; 3:255-268.

41. Ren K: Emerging role of astroglia in pain hypersensitivity. Jpn Dent Sci Res 2010; 46:86.